智飞生物(300122) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥2,374,498,616.11, a decrease of 79.16% compared to ¥11,395,682,504.71 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥305,140,593.28, representing a decline of 120.93% from a profit of ¥1,457,744,248.17 in the previous year[3] - Total operating revenue for the current period is ¥2,374,498,616.11, a significant decrease from ¥11,395,682,504.71 in the previous period, representing a decline of approximately 79.1%[18] - The net profit for the current period is a loss of ¥305,140,593.28, compared to a net profit of ¥1,457,744,248.17 in the previous period, indicating a decline of approximately 120.9%[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥304,155,089.77, a significant improvement of 107.12% compared to a negative cash flow of ¥4,273,676,599.75 in the same period last year[3] - The cash flow from operating activities generated a net cash inflow of ¥304,155,089.77, a recovery from a net outflow of ¥4,273,676,599.75 in the previous period[21] - Cash and cash equivalents at the end of the period increased to ¥3,066,659,017.21 from ¥2,970,554,147.12, reflecting a net increase of ¥367,802,615.23[22] - The company reported a significant increase in cash inflow from financing activities, totaling ¥5,944,474,956.72, compared to ¥4,097,486,152.00 in the previous period, an increase of approximately 45.0%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥48,340,319,843.45, down 3.14% from ¥49,909,613,835.40 at the end of the previous year[3] - As of March 31, 2025, the company's total assets amounted to CNY 48.34 billion, a decrease from CNY 49.91 billion at the beginning of the period, reflecting a decline of approximately 3.13%[14] - The company's total liabilities decreased from CNY 19.08 billion to CNY 17.81 billion, a reduction of about 6.69%[16] - The total equity attributable to the parent company decreased from CNY 30.83 billion to CNY 30.53 billion, a decline of approximately 0.97%[16] Expenses - The company reported a significant increase in financial expenses, which rose to ¥66,268,710.74, an increase of 1011.22% compared to ¥5,963,609.84 in the previous year[8] - Total operating costs increased to ¥2,434,178,574.47 from ¥9,323,352,619.26, marking an increase of about 26.8%[18] - Research and development expenses for the current period were ¥227,359,676.59, slightly down from ¥234,083,332.08 in the previous period, a decrease of about 2.9%[19] - The company experienced a substantial increase in sales expenses, which amounted to ¥429,766,771.06, compared to ¥495,132,349.15 in the previous period, a decrease of about 13.2%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 126,045, with the largest shareholder holding 48.44% of the shares[10] Strategic Moves - The company acquired a 51% stake in Chongqing Chengan Biopharmaceutical Co., Ltd. through a cash capital increase, indicating a strategic move towards market expansion[13] - The company is actively promoting the asset integration of Chongqing Chengan, which is expected to enhance operational efficiency and market presence[13] Other Information - The company has not yet audited the first quarter report, indicating that the financial results are preliminary and subject to change[23]